Korean Drug Co Ltd
KOSDAQ:014570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.4), the stock would be worth ₩7 562.66 (80% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | ₩4 195 |
0%
|
| 3-Year Average | 0.4 | ₩7 562.66 |
+80%
|
| 5-Year Average | 0.5 | ₩9 197.35 |
+119%
|
| Industry Average | 1.5 | ₩25 110.92 |
+499%
|
| Country Average | 1.3 | ₩21 971.44 |
+424%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
K
|
Korean Drug Co Ltd
KOSDAQ:014570
|
45.4B KRW | 0.2 | 7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 13.3 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.2 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 4.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 3.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 3.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.3 |
| 70th Percentile | 2.8 |
| Max | 96 381.4 |
Other Multiples
Korean Drug Co Ltd
Glance View
KOREAN DRUG Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Icheon, Gyeonggi-Do and currently employs 256 full-time employees. The company went IPO on 2000-12-07. The Company’s products portfolio consists of over-the-counter (OTC) medicines, ethical (ETC) medicines and health food, including multi-symptom cold medicines, blood-forming nutrients, treatments for central nervous system, remedies for respiratory diseases, dermatological agents, vitamins, antifungal agents, antipyretics, analgesics, anti-inflammatory drugs, antibiotics, allergic treatments, calcium and vitamin D tablets and home pregnancy test kits, among others.
